Olamkicept, an IL-6 Trans-Signaling Inhibitor, is Effective for Induction of Response and Remission in A Randomized, Placebo-Controlled Trial in Moderate to Severe Ulcerative Colitis

IL-6 trans-signaling blockade inhibits chronic inflammation in human lamina propria1. Trans-signaling inhibition may have safety advantages over pan-IL-6 inhibitors (i.e. IL-6 or IL-6R antibodies) by preserving membrane IL-6R signaling. We evaluated the efficacy and safety of olamkicept, a soluble gp130-Fc fusion protein that inhibits trans-signaling by binding to the IL-6/ soluble IL-6R complex, for induction in active ulcerative colitis (UC).